Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.

about

Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.

Item

http://www.wikidata.org/entity/Q41598367

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Efficacy and tolerability of v ...... bpopulation of the EDGE study.

@en

type

Item

label

Efficacy and tolerability of v ...... bpopulation of the EDGE study.

@en

prefLabel

Efficacy and tolerability of v ...... bpopulation of the EDGE study.

@en

P1476

Efficacy and tolerability of v ...... bpopulation of the EDGE study.

@en

P2093

Christoph Bialek

http://www.w3.org/2001/XMLSchema#string

Ewald Gingl

http://www.w3.org/2001/XMLSchema#string

Helmut Brath

http://www.w3.org/2001/XMLSchema#string

Michael Resl

http://www.w3.org/2001/XMLSchema#string

Michaela Ratzinger

http://www.w3.org/2001/XMLSchema#string

Rudolf Prager

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

10-year follow-up of intensive glucose control in type 2 diabetes

Pragmatic trials--guides to better patient care?

Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)

Making trials matter: pragmatic and explanatory trials and the problem of applicability.

When can odds ratios mislead?

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

P2888

s00508-014-0646-x

P304

250-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00508-014-0646-X

http://www.w3.org/2001/XMLSchema#string

P433

7-8

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25576329

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes